Citigroup’s Tempest Therapeutics TPST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-8
Closed -$13 6249
2026
Q1
$13 Buy
+8
New +$19 ﹤0.01% 5721
2025
Q1
Sell
-75
Closed -$811 5968
2024
Q4
$811 Buy
+75
New +$968 ﹤0.01% 5609
2021
Q1
Sell
-26
Closed -$11K 7363
2020
Q4
$11K Hold
26
﹤0.01% 6929
2020
Q3
$8K Hold
26
﹤0.01% 6779
2020
Q2
$9K Sell
26
-12
-32% -$4.79K ﹤0.01% 7105
2020
Q1
$39K Buy
38
+28
+280% +$40.8K ﹤0.01% 6204
2019
Q4
$13K Buy
10
+8
+400% +$11.3K ﹤0.01% 7118
2019
Q3
$4K Sell
2
-11
-85% -$17.8K ﹤0.01% 7404
2019
Q2
$30K Sell
13
-18
-58% -$53K ﹤0.01% 6871
2019
Q1
$91K Buy
31
+30
+3,000% +$66.3K ﹤0.01% 5842
2018
Q4
$1K Hold
1
﹤0.01% 7600
2018
Q3
$1K Hold
1
﹤0.01% 7686
2018
Q2
$1K Hold
1
﹤0.01% 7552
2018
Q1
$1K Sell
1
-1
-50% -$3K ﹤0.01% 7474
2017
Q4
$8K Hold
2
﹤0.01% 7118
2017
Q3
$8K Sell
2
-1
-33% -$4.28K ﹤0.01% 6758
2017
Q2
$13K Sell
3
-28
-90% -$118K ﹤0.01% 6446
2017
Q1
$169K Sell
31
-10
-24% -$46.6K ﹤0.01% 4802
2016
Q4
$186K Buy
41
+11
+37% +$137K ﹤0.01% 5337
2016
Q3
$623K Buy
30
+9
+43% +$163K ﹤0.01% 3693
2016
Q2
$323K Sell
21
-3
-13% -$68.5K ﹤0.01% 4065
2016
Q1
$679K Buy
24
+12
+100% +$254K ﹤0.01% 3792
2015
Q4
$346K Sell
12
-5
-29% -$165K ﹤0.01% 4240
2015
Q3
$411K Buy
17
+14
+467% +$943K ﹤0.01% 3933
2015
Q2
$269K Buy
3
+2
+200% +$183K ﹤0.01% 4207
2015
Q1
$109K Hold
1
﹤0.01% 4970
2014
Q4
$135K Buy
+1
New +$73.2K ﹤0.01% 5006
2014
Q3
Hold
0
6329
2014
Q2
Sell
-10
Closed -$236K 6392
2014
Q1
$259K Buy
10
+9
+900% +$255K ﹤0.01% 4090
2013
Q4
$26K Buy
+1
New +$27.4K ﹤0.01% 6071
2013
Q3
Hold
0
6980

Other funds holding TPST

Citigroup's TPST Position: Q2 2026 in Review

Citigroup sold out of Tempest Therapeutics (TPST) in Q2 2026, closing a stake of 8 shares — an estimated $13 sold.

Citigroup first reported a position in TPST in Q4 2013 and held it in 29 quarters. The position peaked at $679K in Q1 2016. 21 funds tracked by Wall St. Rank hold TPST as of Q2 2026.

  • Citigroup reported no remaining Tempest Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 8 Tempest Therapeutics shares in Q2 2026, an estimated $13.
  • Citigroup first reported a position in Tempest Therapeutics in Q4 2013 and held it in 29 quarters.
  • Citigroup's Tempest Therapeutics position peaked at $679K in Q1 2016.
  • 21 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.